EXOZYMES INC.

EXOZ ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023
Operating Activities
Net Income $-9.2M $-5.9M $-2.0M
Depreciation & Amortization
Depreciation $288.0K $267.4K $196.9K
Amortization
Stock-Based Compensation $2.0M $1.1M $281.5K
Net Cash from Operating Activities $-6.5M $-8.5M $-1.2M
Investing Activities
Capital Expenditures $169.9K $396.5K $288.7K
Business Acquisitions
Net Cash from Investing Activities $-150.2K $-359.2K $-311.2K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $-27.7K $18.5M $1.0M
Net Change in Cash $-6.7M $9.7M $-492.0K
Free Cash Flow $-6.7M $-8.9M $-1.5M